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1.1. Epidemiology and aetiology 
 
1.1.1. Epidemiology of carcinoma of the uterine cervix in the world 
 
Cervical cancer (CC) is the fourth most common cancer in females, and seventh 
overall. There was an estimated 528,000 new cases in 2012. Large majority (around 85%) of 
CC occurs in the less developed regions. Around 266,000 females died of CC in 2012, 
accounting for 7.5% of all female cancer deaths. About 85% of CC deaths occured in the less 
developed regions (1). 
 
Figure 1. Estimated Cervical Cancer Incidence Worldwide in 2012 (1). 
 
Figure 2. Estimated Cervical Cancer Mortality Worldwide in 2012 (1). 
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Carcinoma of the uterine cervix, unlike the majority of the other carcinomas, mostly 
affects young females (62% of diagnosed women are age 50 or less). Peak incidence is 
between 25 and 29 years of age (2). 
 
1.1.2. Epidemiology of carcinoma of the uterine cervix in Croatia 
 
According to the Croatian National Institute of Public Health data from 2016, the 
incidence of the CC in Croatia is 13.8/100,000. It is the tenth most common type of carcinoma 
in females in Croatia. Mortality of the CC in Croatia is 5.9/100,000. Highest incidence of in 
situ CC is between the age 30 and 34. Ratio of in situ – invasive CC in Croatia is 1:1 (3). 
 
1.1.3. Risk factors 
 
The foremost important risk factor regarding the CC is an infection with human 
papillomaviruses (HPV), especially HPV-16 and HPV-18 (4). HPV can be divided into high-
risk, probable high-risk and low-risk types, regarding the development of the carcinoma. 
High-risk HPV types are: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82. Probable 
high-risk types are: 26, 53 and 66. Low-risk HPV types are: 6, 11, 40, 42, 43, 44, 54, 61, 70, 
72, 81. The most comon HPV types in patients (figure 3.), in descending order of frequency, 
are types 16, 18, 45, 31, 33, 52, 58 and 35 (5). 
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Figure 3. Attribution of carcinogenic HPV types to cervical disease categories (7). 
 
Peak prevalence of infection with HPV is 20-40% in women aged 20 to 30 years, but 
in the majority of these women (80%), the infection is transient and resolves within 12 to 18 
months. Women with persistent oncogenic HPV infection are at risk of developing high-grade 
precancer and ultimately CC (6). HPV type is the strongest factor affecting the risk of viral 
persistence. Women exposed to HPV-16 are consistenly documented to be at increased risk. 
According to Kaiser Permanente cohort follow-up run in the USA, 16-year risk of developing 
CIN 3+ in women of 30 years and younger was 14.6% for women with HPV-16 at the 
baseline, 7.0% for women with other oncogenic types, and 1.8% for women with no HPV 
infection. For women older than 30 years, the risks were 8.5% for HPV-16, 3.1% for other 
oncogenic types, and 0.7% for HPV negative women (7). 
However, according to many authors, HPV alone is not sufficient to induce CC, and 
multifactorial etiology is likely. Even though the incidence of HPV infection in patients with 
CC is approaching 100%, HPV can not stil be found in each and every patient. Other 
important risk factors contributing to the development of the CC are: early onset of sexual 
activity, increased number of sex partners, smoking, oral contraceptive use, genetic 
background (the position of the original squamocolumnar junction – junction in fetal life 
between stratified squamous epithelium of the vagina and ectocervix and columnar epithelium 
of the endocervical canal – determines the extent of cervical squamous metaplasia and is an 
important early influencer of risk for further neoplastic behavior), immunosuppresion – 
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exogenous and endogenous, multiparity and age of first pregnancy, sexually transmitted 
diseases (8). 
 
1.2. Anatomy of female genital tract 
 
1.2.1. Internal female genital organs 
 
The uterus is a pear-shaped, hollow organ situated in the pelvis, between the bladder 
anteriorly and the rectum posteriorly. It is covered posteriorly by serosa or peritoneum, which 
also covers the upper anterior side,while the lower anterior side is connected to the bladder 
via loose connective tissue. The uterus is suspended from the pelvic wall by various 
ligaments. The broad ligaments extend in a wing-like manner from both lateral portions of the 
uterus. At the upper portion, the broad ligaments give rise to the mesosalpinx to which the 
fallopian tubes are connected, and to the suspensory ligaments of the ovary where ovarian 
vessels pass through. At the lower portion broad ligaments give rise to the cardinal ligaments 
which fuse with connective tissue adjacent to the cervix. The round ligaments extend from the 
lateral portions of the uterus, through the broad ligament, to the upper portions of the labia 
majora. The uterosacral ligaments suspend the uterus in the height of the supravaginal portion 
of the cervix. The uterus can be divided in the two main portions: the broad triangular body, 
which makes up the upper two thirds of the uterus, and the narrow cylindrical cervix which 
makes up the lower one third. The wall of the uterus has three distinctive layers: endometrium 
containing abundance of blood vessels and glands, hormonally sensitive bulky myometrium 
composed of smooth muscle, and outermost layer perimetrium. Uterus plays the central role 
in female reproductive tract. It is the place of implantation of the blastocyst and further 
development of embryo and fetus (9,10). 
Ovaries are paired almond shaped organs situated in the upper part of the pelvic 
cavity, on either side of the uterus. They are connected to the uterus via the ovarian ligaments, 
and to the posterior abdominal wall by suspensory ligaments of the ovary. The ovary is the 
place of maturation and release of sex cells as well as of formation and release of female sex 
hormones (9,10). 
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Fallopian tubes are cylindrical organs where fertilization takes place. They can be 
divided in four anatomical regions: the interstitial portion embedded in the uterine wall, the 
isthmus which opens into the ampulla, and infudibulum ending in fimbria. The tubes are lined 
with ciliated cells participating in peristalsis (9,10). 
The vagina is a hollow organ connecting the cervix with the vulva. It is placed 
between the urethra and rectum. It hosts significant portion of the cervix anterosuperiorly. 
Inferior portion of the vagina is a part of perineum (9,10). 
 
1.2.2. External female genital organs 
 
The external genitalia is comprised of the labia majora, labia minora, mons pubis, 
clitoris,  vulvar vestibule and urethral meatus, and glandular structures opening to the vaginal 
vestibule. Beneath these structures lay the fascial and muscular layers of the perineum. The 
muscles of the external genitalia consist of the deep and superficial transverse perineal 
muscles, the ischiocavernosus muscles that cover the crura of the clitoris, and the 
bulbocavernosus muscles lying on either side of vagina covering the vestibular bulbus (9,10). 
 
1.3.  Diagnosis 
 
1.3.1. Screening 
 
The primary goal of screening is to prevent CC by identifying asymptomatic women 
who are at high risk of having or developing a disease and to further asses them, treat them, 
and organize follow-up. It is known nowadays that CC arises from persistent infection with 
HPV and progression of a preinvasive lesion to invasive carcinoma. That is the reason why 
early detection, treatment and follow-up of precancerous lesions is of foremost importance. 
The higher incidence and death rates of CC described in low-income countries are likely to 
result from the lack of organized cervical screening, together with inadequate access to early 
treatment. On the other hand, screening with cervical cytology in many developed countries 
has resulted in significant decrease in incidence, as well as mortality, of CC (7).  
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Methods of screening are: cytology – conventional (Pap smear) and liquid-based 
(LBC), visual screening using 4% acetic acid or Lugol's iodine solution and HPV testing (11).  
The International Agency for Research on Cancer (IARC) recommends starting 
screening at 25 years of age and many countries are starting to apply this recommendation. 
Population-based data have shown limited effectiveness of cytology in women younger than 
25 years of age in preventing invasive cervical cancer before age 30 (11). According to 
nowadays guidelines issued by the American Cancer Society, American Society for 
Colposcopy and Cervical Pathology and American Society for Clinical Pathology, women 
younger than 21 years do not have to be screened, women from 21 to 29 years of age should 
be screened by performing cytological testing alone every three years, women from 30 to 65 
years of age should be screened by performing cytological and HPV co-testing every 5 years 
(preffered) or cytologic testing alone every 3 years (acceptable) (12). In women older than 65 
years, screening can be discontinued if there has been an adequate number of negative 
screening results (3 consecutive negative cytologic tests or 2 consecutive negative co-tests in 
past 10 years, with the most recent test performed in the past 5 years) and if there is no history 
of high-grade squamous intraepithelial lesion, adenocarcinoma in situ, or cancer (12). 
 
1.3.2. Physical examination 
 
Physical examination is of limited value when it comes to the diagnosis of early stage 
CC because of its asymptomatic nature,  but nevertheless should always be performed. 
Besides examining the genital tract and pelvis, it should always include palpation of the liver 
and lymph nodes to exclude metastatic disease (13). 
The first sing of the disease is vaginal discharge not related to menstrual cycle. 
Classical symptoms are painless bleeding, spotting and painful intercourse. As the disease 
progresses, symptoms become more common and more severe, as well as consistent with the 
metastatic spread of the disease (14). 
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1.3.3. Colposcopy 
 
Women with positive / pathologic screening results should be directed to colposcopy. 
It should be kept in mind that if a carcinoma is entirely within the endocervical canal, the 
ectocervix may be colposcopically normal (13). 
 
1.3.4. Biopsy 
 
Any obvious tumor growth or ulceration, as well as any cervix that is unusually firm 
or expanded, should undergo office punch biopsy or loop excision for histologic confirmation 
(13). 
 
1.3.5. Other 
 
In order to be able to plan the treatment it is important to asses the extent of the 
disease. There are different imaging modalities that help us in doing so, one of the most 
commonly used ones being X-ray, Computed Tomography (CT), Magnetic Resonance 
Imaging (MRI) and Positron Emission Tomography (PET) (13). 
 
1.4. Staging 
 
Many different staging systems for CC exist. The FIGO (International Federation of 
Gynecology and Obstetrics) system is the most commonly used one (4). Other staging 
systems are AJCC (American Joint Commitee on Cancer) TNM staging system, SGO 
(Society of Gynecologic Oncology) staging system, and staging system brought by Japanese 
comitee. 
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1.4.1. FIGO staging system 
 
FIGO staging system (table 1.) is the most commonly used staging system for CC. It is 
a clinical staging systemand permits following diagnostic studies in determining the stage: 
physical examination of the pelvis and assessment of lymphadenopathy, colposcopy, 
endocervical curretage, conization, hysteroscopy, cystoscopy, proctoscopy, intravenous 
pyelogram and plain radiographic imaging of the lungs and skeleton. Results from PET 
(Positron Emission Tomography), MRI (Magnetic Resonance Imaging) or CT (Computed 
Tomography) cannot be utilized to assign a FIGO stage (4).  
The FIGO definition for stage IA changed six times between 1961 and 1985 before the 
FIGO 1995 criteria were suggested. The definition of stage IA did not change from 1995 to 
the most current revision in 2009.FIGO stage I is defined as carcinoma strictly confined to the 
cervix. Stage I is further subdivided in stages IA and IB. Stage IA is amicroinvasive 
carcinoma that can be diagnosed only by microscopy, with deepest invasion 5mm or less and 
largest extension not more than 7mm. All macroscopically visible lesions are allocated to 
stage IB. Stage IA is subdivided into 2 subtypes as well: stage IA1 defined as invasive 
carcinoma with stromal invasion of 3.0mm or less in depth and extension of 7.0mm or less, 
and stage IA2 (15).  
FIGO stage is not determined by lymphovascular invasion (LVI), but LVI status 
should be included in pathology reports (16). 
 
1.4.2. AJCC TNM staging system 
 
AJCC TNM staging system (table 2.) is based on tumor size, involvement of the 
lymph nodes and presence of metastases. FIGO stage IA1 corresponds to TNM T1a1* – 
measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread 
(18). 
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1.4.3. SGO staging system 
 
SGO staging system defines microinvasive CC as carcinoma of invasive depth 3 mm 
or less from the basement membrane of the point of origin with no lymphovascular invasion 
present (17). 
 
1.4.4. Japanese comitee staging system 
 
Japanese comitee defines microinvasive CC as stage 1A: depth of the invasion is 3 
mm or less, without lymphovascular invasion (19). 
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Table 1. Revised FIGO classification of carcinoma of the uterine cervix, 2009 (17). 
STAGE I The carcinoma is strictly confined to the cervix 
IA 
 
   IA1* 
 IA2 
IB 
IB1 
   IB2 
Invasive carcinoma that can be diagnosed only by microscopy, with deepest invasion 5 mm or 
less and largest extension not  > 7 mm 
Measured stromal invasion of 3.0 mm or less in depth and extension of 7.0 mm or less * 
Measured stromal invasion of  > 3.0 mm and not > 5.0 mm with an extension of not  > 7 mm 
Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA 
Clinically visible lesion 4.0 cm or less in greatest dimension 
Clinically visible lesion > 4.0 cm in greatest dimension 
STAGE II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower 
third of vagina 
IIA 
   IIA1 
   IIA2 
IIB 
Without parametrial invasion 
Clinically visible lesion 4.0 cm or less in greatest dimension 
Clinically visible lesion > 4.0 cm in greatest dimension 
With parametrial invasion 
STAGE III The tumor extends to the pelvic wall and/or involves lower third of vagian and/or causes 
hydronephrosis or non-functioning kidney 
IIIA 
IIIB 
Tumor involves lower third of vagina, with no extension to the pelvic wall 
Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney 
STAGE IV The carcinoma has extended beyond the true pelvis, or has involved (biopsy-proven) the 
mucosa of the bladder or rectum.  
IVA 
IVB 
Spread of the growth to adjacent organs 
Spread to distant organs 
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Table 2. TNM classification for carcinoma of the uterine cervix (18). 
T (primary tumor)  
TX 
T0 
Tis 
T1 
   T1a 
 
 
 
T1a1* 
 
      T1a2 
 
   T1b 
 
      T1b1 
      T1b2 
T2 
 
   T2a 
   T2b 
T3 
 
 T3a 
   T3b 
 
T4 
Primary tumor can not be assessed. 
No evidence of primary tumor. 
Carcinoma in situ. 
Cervical carcinoma confined to uterus 
Invasive carcinoma diagnosed only by microscopy. All microscopically visible lesions 
– even with superficial invasion – are T1b. Stromal invasion with a maximal depth of 
5 mm, measured from the base of the epithelium, and a horizontal spread of 7 mm or 
less.  
Measured stroml invasion 3 mm or less in depth and 7 mm or less in horizontal 
spread.* 
Measured stromal invasion > 3 mm and not > 5 mm, with a horizontal spread 7 mm or 
less. 
Clinically visible lesion confined to the cervix, or microscopic lesion greater than 
T1a2. 
Clinically visible lesion 4 cm or less in greatest diameter. 
Clinically visible lesion > 4 cm in greatest dimension. 
Cervical carcinoma invades beyond uterus but not to pelvic wall or to the lower 
third of vagina. 
Tumor without parametrial invasion. 
Tumor with parametrial invasion. 
Tumor extends to the pelvic wall and/or involves the lower third of vagina, 
and/or causes hydronephrosis or non-functional kidney. 
Tumor involves lower third of vagina; no extension to pelvic wall. 
Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning 
kidney. 
Tumor invades mucosa of the bladder or rectum and/or extends beyond true 
pelvis. 
N (regional lymph 
      nodes) 
 
NX 
N0 
N1 
Regional lymph nodes can not be assessed. 
No regional lymph node metastasis. 
Regional lymph node metastasis. 
M (distant 
metastasis) 
 
MX 
M0 
M1 
Distant metastasis can not be assessed. 
No distant metastasis. 
Distant metastasis. 
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1.5. Pathohistology 
 
The most common primary CC is squamous cell carcinoma. It comprised more than 
90% of cervical cancers a few decades ago, but nowadays, owing to the effective cytologic 
detection, the incidence is steadily decreasing. The incidence of cervical adenocarcinoma, on 
the other hand, is increasing significantly. Other neoplasms affecting the cervix are 
neuroendocrine, mesenchymal and metastatic tumors (20). 
 
1.5.1. Squamous cell carcinoma of the uterine cervix 
 
Squamous cell carcinoma is the most common primary malignancy of the uterine 
cervix. Most cervical squamous cell carcinomas originate from the metaplastic squamous 
epithelium located between the original and new squamocolumnar junctions, the 
transformation zone (20).  
 
1.5.1.1. Cervial intraepithelial lesions 
 
Cervical intraepithelial lesions, that affect millions of women yearly,  have 
traditionally been classified using a three tiered system (originally 
mild/moderate/severedysplasia, subsequently CIN 1/2/3), corresponding to a stepwise 
progression from intraepithelial lesion of grading severity to invasive carcinoma. In 2012, a 
new consensus about the terminology was brought in order to standardize the diagnosis – 
LAST (Lower Anogenital Squamous Terminology) project. The result was the change to two-
tiered nomenclature – low-grade squamous intraepithelial lesion (LSIL) and high-grade 
squamous intraepithelial lesion (HSIL). Histologic LSIL corresponds to CIN1, including both 
mild dysplasia and HPV cytopathic effect without dysplasia. Histologic HSIL corresponds to 
CIN2 and CIN3, and includes spectrum from moderate dysplasia to carcinoma in situ (21). 
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1.5.1.2. Squamous cell carcinoma 
 
There are many different variants of squamous cell carcinoma of the uterine cervix. 
The one that is of the great interest in last years is superficially invasive squamous cell 
carcinoma (SISCC), also known as microinvasive carcinoma. This type of CC is of emerging 
importance because its presence offers the ability to manage the patients with more 
conservative treatment while stil having a low risk of lymph node metastases and recurrence 
(21).  
Invasive squamous cell carcinoma is characterized by infiltrating nests of neoplastic 
epithelium in the stroma. Many different types of squamous cell carcinoma are known, some 
of which being keratinized SCC, non-keratinizing SCC, veruccous SCC, papillary SCC and 
basaloid SCC (21). 
 
1.5.2. Adenocarcinoma of the uterine cervix 
 
Adenocarcinomas currently account for 15-20% of all invasive CC in developed 
countries (22). They typically occur within the endocervical canal (21). 
Microinvasive adenocarcinoma of the uterine cervix is defined by Teshima and 
associates as less than 5 mm stromal invasion as measured from the mucosal surface (23). 
FIGO staging system is applicable for adenocarcinomas as well. In contrast, the SGO 
microinvasive carcinomas classification is not applicable to adenocarcinomas (17).  
Invasive adenocarcinoma of the uterine cervix is present when individual cells or 
incomplete glands of malignant cells are identified coursing thorugh the stroma. Alternatively, 
adenocarcinoma can also be identified when malignant glands are found coursing through a 
desmoplastic stroma, indicating a host response. Many invasive adenocarcinomas do not 
exhibit either of these two features, and in this case diagnosis is based on a third, more 
subjective criterion, that is the identification of different abnormal patterns of malignant 
glands that do not conform to the lobular configuration of normal endocervical glands. The 
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fourth possible criterion is the presence of malignant glands beneath the deep margin of 
normal endocervical glands (17).  
 
1.6. Treatment 
 
Treatment of the CC is a complex and multidisciplinary field. The most important 
factor in choosing the treatment is the stage of CC. Other factors can and should affect the 
decision-making process as well, including the exact location of the cancer within the cervix, 
the type of cancer, age of the patient, overall health of the patient, and whether the fertility is 
to be maintained or not (24). Treatment decision should also be made according to current 
algorithms of the institution in which the treatment is undertaken. The decision is, in most 
cases, brought by a team of specialists including gynecologist, anesthesiologist, radiologist, 
pathologist, cytologist, and other if necessary (25).  
For early stages of the disease, it is enough to perform loop electrosurgical excision of 
transformation zone (LEETZ) or conization, or simple hysterectomy (surgical removal of the 
cervix and uterus only) for women older than 45 years of age in whom there is no need for 
fertility preservation. In the case of the advanced disease, neoadjuvant radiotherapy followed 
by radical hysterectomy (surgical removal of the cervix, uterus, vaginal cuff, pelvic lymph 
nodes, obturator lymph nodes, paracervical tissue and parametrial tissue) should be done. In 
the final stages of the disease, palliative treatment with radiotherapy or chemotherapy is the 
treatment of choice (6,26). 
 
1.6.1. Treatment of carcinoma of the uterine cervix FIGO IA1 
 
Treatment of carcinoma of the uterine cervix FIGO IA1 depends on whether or not  
fertility is to be maintained and whether or not the cancer has grown into blood or lymph 
vessels (lymphovascular invasion) (24). 
For women who want to preserve fertility, conization or LEETZ is the preferred 
procedure. If the margins are negative, woman can be watched closely without further 
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treatment. If the margins are positive, the carcinoma should be treated either by repeated 
conization or LEETZ or by simple hysterectomy. Simple hysterectomy is preferred if there is 
lymphovascular invasion (27). Proven complication of conization or LEETZ is a negative 
effect on pregnancy. Compared with women who have not received treatment, women who 
have recieved cold-knife conisation or LEETZ have significantly higher rates of preterm 
delivery and infants with low birth weight. Analysis by depth of incised tissue found that risks 
of preterm delivery increased further if the depth was more than 10 mm (6). 
For women who do not want to preserve fertility,  the treatment of choice is simple 
hysterectomy. If there is lymphovascular invasion, the patient might need a radical 
hysterectomy and pelvic lymphadenectomy(27). 
 
1.7. Follow-up 
 
Theguidlines from 2017 recommend following steps regarding the follow-up of 
patients treated for CC: follow-up of patients with FIGO stage I disease depends on whether 
the patients received fertility sparing or non-fertility sparing treatment (28). If the patient 
underwent fertility-sparing treatment, pelvic MRI with contrast should be considered 6 
months after surgery and then yearly for 2-3 years, if metastasis is suspected whole body 
PET/CT should be considered, other imaging should be based on symptomatology and 
clinical concern for recurrent/metastatic disease (factors that should rise clinical concern are 
abnormal physical exam findings or new pelvic, abdominal or pulmonary symptoms). In the 
case when the patient underwent non-fertility sparing surgery imaging should be based on 
symptomatology and clinical concern for recurrent/metastatic disease (28). For patients with 
FIGO stage IB2 or patients who required postoperative adjuvant radiation or chemoradiation 
due to high risk factors (high risk factors include positive nodes, positive parametria, positive 
margins or local cervical factors), whole body PET/CT may be performed at 3-6 months after 
completion of treatment (28). Regarding the follow-up of patients with FIGO stage II-IV, 
whole body PET/CT is advised within 3-6 months of completion of therapy. Other imaging 
should be based on symptomatology and clinical concern for recurrent/metastatic disease 
(factors that should rise clinical concern may be abnormal physical exam findings such as 
palpable mass or adenopathy, or new pelvic, abdominal, or pulmonary symptoms) (28). 
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1.8. Prognosis 
 
The prognosis of the carcinoma of the uterine cervix depends on the stage of the 
disease. The 5-year survival rate for stage I carcinoma of the uterine cervix is  80-93%. For 
stage II survival rate is 58-63%. For stage III survival rate is 32-35%. Stage IV has a survival 
rate about 15%. There is a significant decrease in the 5-year survival rate between stage I and 
stage IV, which emphasizes once again the importance of screening and early diagnosis and 
treatment of the carcinoma of the uterine cervix (Table 3.) (29). 
 
Table 3. 5-year survival of the carcinoma of the uterine cervix patients by FIGO stage (29). 
FIGO stage  5-year survival rate 
Stage I 
IA 
      IB  
 
93% 
80% 
Stage II 
      IIA 
      IIB 
 
63% 
58% 
Stage III 
      IIIA 
      IIIB 
 
35% 
32% 
Stage IV 
      IVA 
      IVB 
 
16% 
15% 
 
 
1.9.  Prevention 
 
The natural history of the CC offers a variety of opportunities for prevention of the 
disease. It is known that persistent infection with high-risk HPV types leads to the 
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development of the carcinoma. The possibilities of primary prevention are the prevention of 
acquiring the HPV infection by education of adolescents, vaccination and development of 
effective vaginal microbicide.Cervical screening and early therapy are also a form of 
prevention and may lead to significant decrease in both incidence and mortality (30).   
In Croatia, it is advised for women to be examined by their gynecologist and to do the 
Pap smear every 1-3 years from the onset of sexual activity or from the age 18 on. After 3 or 
more negative Pap smear results, the time between the two consecutive testings can be 
increased, but it should not exceed 3 years. Women with higher risk for developing the 
disease should be screened more often (31).  
Vaccination against HPV is recommended for girls and boys ages 11 or 12, although 
some organizations recommend starting vaccination as aearly as age 9 or 10. Girls and boys 
should recieve the vaccine before they have sexual contact because once someone is infected 
with the virus, the vaccine might not be as effective or might not work at all. Nevertheless the 
vaccination is stil advised because even if people have already been infected with one or more 
HPV types they can stil get protection from other HPV types in the vaccine. Currently 
available HPV vaccines are bivalent, quadrivalent and nine-valent. All of them protect against 
HPV types 16 and 18, quadrivalent vaccine also protects against HPV types 6 and 11, and 
nine-valent targets five additional cancer-causing types (32). 
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2. OBJECTIVES 
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The aim of this paper is to examine the incidence of microinvasive carcinoma of the 
uterine cervix FIGO stage IA1 treated at the University Hospital of Split from 1.1.2000. to 
1.1.2017., to examine the age of the patient at the diagnosis, to examine the incidence of 
patohistological types, to examine the incidence of lymphovascular invasion, and to examine 
the treatment choice.  
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3. METHODS 
 
22 
 
By retrospective analysis of medical histories and discharge letters of all patients with 
the carcinoma of the uterine cervix FIGO stage IA1 from 1.1.2000. to 1.1.2017., the following 
will be examined: 
- the age of the patient at the diagnosis 
- patohistological diagnosis 
- lymphovascular invasion (LVI) 
- treatment choice. 
The main data source for this paper are medical histories and discharge letters and the 
protocol of surgeries of patients with carcinoma of the uterine cervix FIGO stage IA1, 
assessed from the archives of the Department of Gyneacology and Obstetrics and Department 
of Oncology in University Hospital of Split. 
Statistical analysis was performed using NCSS statistical software, version 12.0.8. 
Descriptive methods were used to analayse the data from this study. Lilliefors test was used to 
assess the normality of data distribution. 
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4. RESULTS 
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In total 67 women with the CC FIGO stage IA1 have been diagnosed and treated at the 
Department of gynaecology and obstetrics and Department of Oncology in University 
Hospital of Split in the time span of 17 years. The highest number of diagnosed CC was in 
year 2011 (n=8), followed by year 2009 (n=7), and the lowest number was diagnosed in year 
2002 (n=1) (Figure 4). 
 
 
Figure 4. The number of patients with the carcinoma of the uterine cervix in years from 2000 
to 2017 
 
4.1. Age of patients 
 
The youngest and the oldest age groups are 21-30 years of age and 71-80 years of age, 
respectively. The greatest incidence of CC was in age group 41-50 years of age (21 out of 
67;31%), followed by age group 31-40 years of age (20 out of 67;30%), and the lowest 
incidence was in the age group 21-30 years of age (3 out of 67;5%) (Figure 5). 
 
N 
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Figure 5. The incidence of the carcinoma of the uterine cervix in different age groups 
 
The median age of the patients diagnosed with the carcinoma of the uterine cervix in 
the clinical hospital Split from 1.1.2000. to 1.1.2017. was 46 years (IQR 36-56). 
 
4.2. Pathohistology 
 
Squamous cell carcinoma was the most common type of the carcinoma of the uterine 
cervix in our patients (60 out of  67;90%). Adenocarcinoma was diagnosed in 6 patients (6 out 
of 67;9%). The third type of cancer diagnosed in our patients was adenosquamous carcinoma 
(1 in 67;1%). There were no other pathohistological types diagnosed in this period of time 
(Figure 7).  
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Figure 7. The incidence of pathohistological types of the carcinoma of the uterine cervix 
 
4.3. Lymphovascular invasion 
 
The majority of our patients were diagnosed with carcinoma which did not show signs 
of lymphovascular invasion (60 out of 67;90%). The minority of patients had cancer with 
evident lymphovascular invasion (7 out of 67;10%) (Figure 8.). 
 
 
 
 
 
 
 
 
Figure 8. Lymphovascular invasion 
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Table 4 describes the relationship between the lymphovascular invasion and the 
histological type of the carcinoma. Fifty-four out of 60 squamous cell carcinoma did not show 
signs of lymphovascular invasion and only 6 of them were positive for lymphovascular 
invasion. Seven out of 7 adenocarcinomas did not show signs of lymphovascular invasion. 
The only one diagnosed adenosquamos carcinoma was positive for lymphovascular invasion. 
 
Table 4. Lymphovascular invasion in relation to the pathohistological type of carcinoma 
PhD Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma 
LVI+ 6 0 1 
LVI- 54 6 0 
 
 
The incidence of lymphovascular invasion of different pathohistological types is presented in 
figure 9. Ninety percent of squamous cell carcinoma were negative for lymphovascular 
invasion and 10% had positive lymphovascular invasion. One hundred percent of 
adenocarcinoma and adenosquamous carcinoma were negative for lymphovascular invasion 
or had positive lymphovascular invasion, respectively.  
 
Figure 9. The incidence of LVI of different pathohistological types 
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4.4. Treatment 
 
The most common surgical option overall was conization (39 out of 73;58%). 
Hysterectomy was performed in 25 out of 73 cases (37%), LEETZ in 5 out of 73 cases (8%), 
excochleation in 3 out of 73 cases (5%) and adjuvant radiotherapy was performed in only one 
case (1 out of 67;2%) (Table 5).  
 
Table 5. Treatment options used for patients with the carcinoma of the uterine cervix FIGO 
IA1 from 1.1.2000. to 1.1.2017. in University Hospital of Split 
Treatment options n % 
Conization 39 58 
Hysterectomy 
LEETZ 
25 
5 
37 
8 
Excochleation 3 5 
Adjuvant radiotherapy 1 2 
 
The choice of treatment and its relationship with the pathohistological type of 
carcinoma is presented in figure 10. The choice of treatment for squamous cell carcinoma was 
conization in most of the cases (32 out of 60;53%), followed by hysterectomy (23 out of 
60;38%), LEETZ (5 out of 60;8%), excochleation (3 out of 60; 5%) and adjuvnt radiotherapy 
which was used only once (1 out of 60;2%). All adenocarcinomas were treated with 
conization (6 out of 6;100%) as well as all adenosquamous carcinomas (1 out of 1;100%).  
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Figure 10. The incidence of different treatment options in relation to pathohistological type 
 
Figure 11 shows the treatment option and its relationship with the lymphovascular 
invasion. Carcinomas with positive lymphovascular invasion (7 out of 67;10%) were in most 
cases treated by conization (5 in 7;71%), followed by hysterectomy (3 in 7;43%) and 
excochleation (1 in 7;14%). LEETZ and adjuvant radiotherapy were not used as a treatment 
for carcinomas with positive lymphovascular invasion. Carcinomas with negative 
lymphovascular invasion (60 out of 67;90%) were treated by conization in most cases (34 in 
60;57%) as well, followed by hysterectomy (23 in 60;38%), LEETZ (5 in 60;8%), 
excochleation (2 in 60; 3%) and adjuvant radiotherapy was used in one occasion (1 in 60;2%). 
N 
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Figure 11. The incidence of different treatment options based on lymphovascular invasion 
 
Figure 12 shows the treatment option and its relationship to the age of the patient. In 
age group 21-30 years of age conzation was used as an only treatment option (3 in 3;100%). 
In age group 31-40 years of age the most common treatment option used was conization (18 
in 20;90%), followed by LEETZ (2 in 20;10%), hysterectomy (1 in 20;11%) and 
excochleation (1 in 20;11%). Adjuvant radiotherapy was not used in this age group. In age 
group 41-50 years of age the most common treatment option used was conization (10 in 
21;48%), followed by hysterectomy (9 in 21;43%) and LEETZ (2 in 21;10%). Excochleation 
and adjuvant radiotherapy were not used as a treatment option in this age group. In age group 
51-60 years of age most common treatment option used was hysterectomy (7 in 9;78%), 
followed by conization (3 in 9;33%), excochleation (1 in 9;11%) and adjuvant radiotherapy (1 
in 9;11%). LEETZ was not used as a treatment option in this age group. In age group 61-70 
years of age conization (4 in 8;50%) and hysterectomy (4 in 8;50%) were the only treatment 
options used. LEETZ, conization and adjuvant radiotherapy were not used as a treatment 
options in this age group. In age group 71-80 years of age the most common treatment option 
used was hysterectomy (4 in 6;67%), followed by LEETZ (1 in 6;17%) and conization (1 in 
6;17%). Excochleation and adjuvant radiotherapy were not used as treatment options in this 
age group. 
N 
31 
 
 
 
 
Figure 12. The incidence of different treatment options used in relation to the age of the 
patient 
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5. DISCUSSION 
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Carcinoma of the uterine cervix is one of the most commonly diagnosed carcinomas in 
females worldwide (3). In period of 17 years (1.1.2000.-1.1.2017.), 67 women in total were 
diagnosed with and treated for the CC in University Hospital of Split, Department of 
Gyneacology and Obstetrics.  
The peak incidence of the CC in our hospital is between 41 and 50 years age, youngest 
age being 26 years and oldest age being 79 years, median age being 46 years. In the UK and 
the majority of the rest of the European Union member countries, based on the data from 
Office for National Statistics, the median age is 45 years (2). We conclude that, in Croatia, the 
results are similar to the results in the rest of the Europe.In Croatia, screening protocol is in 
concordance with screening protocols in the rest of the World, which could be the explanation 
for these findings (12). 
In our hospital, the most common pathohistological type of the CC is squamous cell 
carcinoma, it occurs in 90% of cases (60 out of 67 women were diagnosed with  squamous 
cell carcinoma), followed by adenocarcinoma occuring in 9% of cases (6 out of 67 women 
were diagnosed with adenocarcinoma) and there was only one case of adenosquamous 
carcinoma. Our results do not differ much from the results brought by other authors. 
Squamous cell carcinoma is the most common type of the CC worlwide (6,20). Articles 
published by International Agency for Research on Cancer (IARC) state that more than two-
thirds of the CC are squamous cell carcinomas, and about 15% are adenocarcinomas (33,34). 
Many differences exist between squamous cell carcinoma and adenocarcinoma of the 
uterine cervix, including anatomic origin, risk factors, prognosis, dissemination, sites of 
recurrence and rates of metastases. These differences are sufficient to warrant specific 
treatment recommendations. Nevertheless, despite differences, the lack of data evaluating 
adenocarcinoma is the reason why current treatment algorithms do not distinguish between 
squamous cell carcinoma and adenocarcinoma of the uterine cervix (35). The management of 
microinvasive adenocarcinoma of the uterine cervix remains controversial, and radical 
therapy is applied more frequently than is the case with squamous cell carcinoma, even 
though the data shows that the risk of the extracervical disease is low and the risk of 
recurrence is not affected by the radicality of resection and that microinvasive 
adenocarcinoma is amenable to treatment with nonradical surgery (36). In our hospital it is 
well recognized that microinvasive adenocarcinoma is amenable to nonradical treatment and 
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that radical resection is not the proper treatment option. Hundred percent of microinvasive 
adenocarcinomas diagnosed in University Hospital of Split was treated by conization. 
Lymphovascular invasion, together wih the depth of stromal invasion and tumor 
diameter, is an independent risk factor because of its frequent association with increased 
incidence of lymph node metastases, recurrence and poor survival. The depth of stromal 
invasion is the most critical of these risk factors (37). Sixty out of 67 of our patients had 
negative lymphovascular invasion (90%) and only 7 out of 67 of them had positive 
lymphovascular invasion (10%). Most of the squamous cell carcinomas, 90% of them, were 
negative for lymphovascular invasion. All of the adenocarcinomas diagnosed in our patients 
were negative for lymphovascular invasion. The only one adenosquamous carcinoma 
diagnosed was positive for lymphovascular invasion. Lymphovascular invasion is one of the 
factors that should lead our decision when it comes to choosing the most appropriate 
treatment option for our patient. In the case of the positive lymphovascular invasion, simple 
hysterectomy is the preferred option (27), but its presence should not be considered as a 
contraindication for conization in patients with carcinoma of the uterine cervix FIGO stage 
IA1, rather it should impose the requirement for pelvic lymph node sampling, because 
positive lymph nodes per se are a contraindication for sparing procedures (38). In our 
hospital, majority of patients were treated with conization regardless of the status of 
lymphovascular invasion. Fifty-seven percent of our patients with negative lymphovascular 
invasion and 71% with positive lymphovascular invasion were treated with conization.. 
Second most common procedure performed was hysterectomy. Hysterectomy was performed 
in 38% of patients with negative lymphovascular invasion and in 43% of patients with 
positive lymphovascular invasion. 
Treatment of the CC is a complex and multidisciplinary field. The decision about the 
treatment should be made by a team of specialists and according to the current algorithms of 
the institution where the treatment is to be performed (25). Factors that should affect the 
decision-making process when it comes to choosing the most appropriate treatment option for 
our patient are: the stage of the carcinoma (being the most important factor), exact location of 
the carcinoma within the cervix, the type of carcinoma, lymphovascular invasion status of the 
carcinoma, age of the patient, overall health of the patient and whether the fertility is to be 
maintained or not (24).  
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For the CC FIGO stage IA1 it is enough to perform LEETZ or conization or simple 
hysterectomy, according to the guidelines (6,26). The most common procedure performed in 
our hospital was conization. Conization was the preferred option in 58% of cases. Second 
most common treatment performed was hysterectomy, in 37% of cases.The results from this 
paper show that in our hospital the decision about the treatment follows the guidelines and 
does not differ much from the rest of the world. The only difference is that in our hospital, 
LEETZ is preferred option in only 8% of cases. There is no data to explain this finding.  
For women who wish to preserve fertility, conization or LEETZ is the preferred 
treatment option. If the margins are negative, no further treatment is required. If margins are 
positive, repeated conization or LEETZ or simple hysterectomy should be performed. For 
women who do not wish to preserve fertility, the treatment of choice is simple hysterectomy 
(27). Fertility is defined as the capacity to concieve or to induce conception.Fertile women are 
considered to be in childbearing age. Childbearing age is the period in a woman's life between 
puberty and menopause. A woman of childbearing age is usually considered to be between 
ages 15 and 44, it should be noted that these numbers are used only as a generalized 
guidelines, and women can have offspring earlier as well as later than the years indicated. In 
Clinical hospital Split, the age of the patient is the factor participating in the guidance of the 
treatment decision-making process as well. Women in the age group 21-50 years of age, 
roughly representing the childbearing age group, were most commonly treated with 
conization, being one of the fertility sparing procedures. The younger the patient was, 
conization was more commonly used as a tretment option. In age group 21-30 years of age all 
patients were treated by conization. The most common treatment option for women older than 
51 years of age, roughly representing the non-childbearing age group, was hysterectomy. We 
can conclude that in our hospital, the age of the patient is the important factor when it comes 
to deciding about the most proper treatment option and that it correlates with the guidelines in 
the rest of the world (27). 
 
 
. 
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION 
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1. In the period of 17 years, 67 women in total were diagnosed with and treated for the 
carcinoma of the uterine cervix FIGO stage IA1 in University Hospital of Split, 
Department for Gynaecology and Obstetrics. 
2. The youngest patient diagnosed with the carcinoma of the uterine cervix FIGO stage 
IA1 was 26 years old, and the oldest was 79 year old. The median age of our patients 
was 46 years. 
3. The most common type of the carcinoma was squamous cell carcinoma, diagnosed in 
90% of cases. Adenocarcinoma was diagnosed in 9% of cases. Adenosquamous 
carcinoma was diagnosed in only one patient,  1% of cases.  
4. Most of the diagnosed carcinomas were negative for lymphovascular invasion (90%), 
and only a minority was positive (10%). 
5. The most common treatment option used in our hospital for the carcinoma of the 
uterine cervix FIGO stage IA1 was conization, followed by hysterectomy, LEETZ and 
excochleation. Thirty-nine conizations, 25 hystrectomies, 5 LEETZ procedures and 3 
excochleation were performed. In addition, radiotherapy was used as an adjuvant 
treatment in te case of one of our patients. 
6. Conization was the most common procedure used regardless of the pathohistological 
type and lyphovascular invasion of the carcinoma. 
7. Women younger than 50 years of age were most commonly treated with conization, 
being the fertility sparing procedure. Women older than 51 year of age were most 
commonly treated with hysterectomy, being the non-fertility sparing procedure. 
8. In our hospital the approach to prevention, diagnosis and treament of the carcinoma of 
the uterine cervix is in concordance with the protocols used in the rest of Europe and 
the World, and all the results from this paper are similar to the results of other studies. 
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8. SUMMARY 
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Title: MICROINVASIVE CARCINOMA OF THE UTERINE CERVIX IN UNIVERSITY 
HOSPITAL OF SPLIT 
Objectives:The aim of this paper is to examine the incidence of microinvasive carcinoma of 
the uterine cervix FIGO stage IA1 treated in University Hospital of Split from 1.1.2000. to 
1.1.2017., to examine the age of the patient at the diagnosis, to examine the incidence of 
patohistological types, to examine the incidence of lymphovascular invasion, and to examine 
the treatmet choice.  
Methods: By retrospective analysis of histories and discharge letters and the protocol of 
surgeries of all patients with the CC FIGO stage IA1, assessed from the archives of the 
Department of Gyneacology and Obstetrics and Department of Oncology in Clinical hospital 
Split, we examined the following: the age of the patients at the diagnosis, pathohistological 
diagnosis, lymphovascular invasion and treatment choice. 
Results:In total 67 women were diagnosed with and treated for the CC FIGO stage IA1 at the 
Deparment of Gynaecology and Obstetrics and Department of Oncology in Clinical hospital 
Split in period of 17 years. The highest number of diagnosed carcinomas was in year 2011 
(n=8), and the lowest in year 2002 (n=1). The greatest incidence of the carcinoma was in age 
group 41-50 years of age (21 out of 67;31%). The youngest patient was 26 years old and the 
oldest was 79 years old, median age was 46 years (IQR 36-56). The most common type of 
carcinoma was squamous cell carcinoma (60 out of 67;90%). Most of the diagnosed 
carcinomas were negative for lymphovascular invasion (60 out of 67;90%). The most 
common surgical procedure used was conization (39 out of 73;58%). Conization was the most 
common surgical option used regardless of pathohistological type and LVI. Conization was 
the only treatment option used in age group 21-30 years (3 out of 3;100%). Conization was 
the most common treatment option used in age groups 31-40 years (18 out of 20;90%) and 
41-50 years (10 out of 21;48%). The most common treatment option used in age group 51-60 
years was hysterectomy (7 out of 9;78%). Age group 61-70 years was equally as often treated 
with conization (4 out of 8;50%) as it was with hysterectomy (4 out of 8;50%). The most 
common treatment option in age group 71-80 years of age was hysterectomy (4 out of 
6;67%). 
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Conclusions: In the period of 17 years, in total 67 women were diagnosed with and treated 
for the carcinoma of the uterine cervix FIGO stage IA1 in our hospital. The median age of our 
patients was 46 years. The most common type of carcinoma was squamous cell carcinoma. 
Most carcinomas were negative for lymphovascular invasion. The most common treatment 
option overall and regardless of pathohistological diagnosis and lymphovascular invasion was 
conization. Women younger than 50 years of age were most commonly treated with 
conization, while women older than 51 years of age were most commonly treated with 
hysterectomy. 
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9. CROATIAN SUMMARY 
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Naslov:MIKROINVAZIVNI KARCINOM VRATA MATERNICE U SVEUČILIŠNOJ 
BOLNICI SPLIT 
Ciljevi:Cilj istraživanja je ispitati pojavnost mikroinvazivnog karcinoma vrata maternice 
FIGO stadija IA1 liječenog u Sveučilišnoj bolnici Split od 1.1.2000. do 1.1.2017. godine, 
ispitati: dob pacijentica pri dijagnozi,učestalost patohistološke dijagnoze, učestalost 
limfokapilarne invazije i odabir liječenja. 
Metode:Retrospektivnom analizom povijesti bolesti i otpusnih pisama i protokola operacija 
svih pacijentica s karcinomom vrata maternice FIGO stadij IA1, kojima je pristupljeno putem 
ulaska u arhive Odjela za Ginkologiju i Obstetriciju i Odjela za Onkologiju KBC-a Split, 
ispitali smo: dob pacijentica pri dijagnozi, patohistološku dijagnozu, limfokapilarnu invaziju i 
odabir liječenja. 
Rezultati:Ukupno 67 žena liječeno je od karcinoma vrata maternice FIGO stadij IA1 na 
Odjelu za Ginekologiju i Obstetriciju i na Odjelu za Onkologiju KBC-a Split u periodu od 17 
godina. Najveći broj dijagnosticiranih karcinoma bio je u 2011. godini (n=8), a najmanji u 
2002. godini (n=1). Najveća pojavnost karcinoma bila je u dobnoj skupini 41-50 godina (21 
od 67;31%). Najmlađa pacijentica imala je 26 godina, a najstarija 79 godina, srednja dob bila 
je 46 godina (IQR 36-56). Najčešći tip karcinoma bio je karcinom pločastih stanica (60 od 
67;90%). Većina dijagnosticiranih karcinoma bila je negativna za limfokapilarnu invaziju (60 
od 67;90%). Najčešći kirurški postupak bila je konizacija (39 od 73;58%). Konizacija je bila 
najčešći kirurški postupak bez obzira na patohistološku dijagnozu i LKI karcinoma. 
Konizacija je bila jedini kirurški postupak učinjen u dobnoj skupini 21-30 godina (3 od 
3;100%). Konizacija je bila najčešći učinjeni kirurški postupak u dobnim skupinama 31-40 
godina (18 od 20;90%) i 41-50 godina (10 od 21;48%). Najčešći kirurški postupak učinjen u 
dobnoj skupini 51-60 godina bila je histerektomija (7 od 9;78%). U dobnoj skupini 61-70 
godina, konizacija i histerektomija učinjene su jednako mnogo puta (4 od 8;50%). Najčešća 
kirurška opcija u dobnoj skupini 71-80 godina bila je histerektomija (4 od 6; 67%): 
Zaključci: U razdoblju od 17 godina, 67 žena je dijagnosticirano i liječeno od karcinoma 
vrata maternice FIGO stadij IA1 u našoj bolnici. Srednja dob naših pacijentica bila je 46 
godina. Najčešći tip karcinoma je karcinom pločastih stanica. Većina karcinoma bila je 
negativna za limfokapilarnu invaziju. Najčešće učinjena operacija, bez obzira na 
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patohistološku dijagnozu i limfokapilarnu invaziju bila je konizacija. Žene mlađe od 50 
godina najčešće su liječene konizacijom, dok su one starije od 51 godina najčešće liječene 
histerektomijom. 
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